Tetrahedron 68 (2012) 4042-4047

Contents lists available at SciVerse ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

DABCO-catalyzed C–C bond formation reaction between electron-deficient alkynes and 1,3-dicarbonyl compounds

Hua Cao*, Haiping Zhong, Yuanguang Lin, Liuqing Yang

School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, No. 280 Wai Huan Dong Lu, Guangzhou 510006, PR China

ARTICLE INFO

Article history: Received 9 January 2012 Received in revised form 12 March 2012 Accepted 15 March 2012 Available online 28 March 2012

ABSTRACT

An excellent catalyst DABCO has been found to catalyze C–C bond formation reaction between activated methylenes and alkynes. The transformation has provided a facile route for the synthesis of 2*H*-pyran-2-ones or unsaturated alkenoic acid ester derivatives and explored the new possibilities of *N*-catalysts for Michael addition of nucleophiles with alkynoates.

Crown Copyright © 2012 Published by Elsevier Ltd. All rights reserved.

1. Introduction

Carbon-carbon bond formation reactions catalyzed by organocatalysts¹ are continuing to attract the attention of synthetic chemists because they have showed great efficiency toward these processes without the use of highly toxic metallic catalysts.² Hillman-Baylis reaction is the most successful example to induce this kind of transformation.³ However, the addition between activated alkynes and methylenes stays surprisingly underdeveloped compared to the great progress that has been made in Michael addition of nucleophiles with alkenoates.⁴ The severe lack of research on this subject probably attributes to the high reactivity of alkynes, which may lead to the chaos of reaction system. Recently, Frederic Taran and co-workers reported that phosphine ligand would facilitate addition of 1,3-dicarbonyl to electron-deficient alkynes via an active phosphonium intermediate.⁵ Jiang also presented the addition of acetylacetone to electron-deficient alkynes that can be used to catalyze by *II*-TPP.⁶ These researches pique our attention and make us wonder if we can catalyze the addition by using nitrogen based organocatalysts.

On the other hand, organic chemists have used this addition to prepare 2*H*-pyran-2-ones, which are one of the most important classes of heterocyclic compounds⁷ and worth our attention because they have exhibited a wide range of biological activities.⁸ Due to the existence of the functional groups, such as conjugated dienes and the ester group, 2*H*-pyran-2-ones are usually utilized as important intermediates in modern organic chemistry.^{8c,9} Recently, Prof. Jiang has developed one-pot transition-metal-catalyzed domino reactions for synthesis of highly functionalized heterocyclic compounds from activated methylenes¹⁰ and electron-deficient

alkynes.¹¹ However, the development of new and efficient catalytic system for synthesis of 2*H*-pyran-2-ones is still a challenging target via carbon—carbon bond formation reaction between activated methylenes and alkynes. Herein, we wish to report our investigation on synthesis of 2*H*-pyran-2-ones by DABCO-catalyzed.

2. Results and discussion

As a model reaction, we investigated the addition of cyclohexane-1,3-dione (1a) to dimethyl but-2-ynedioate (2a) using various nitrogen-based organocatalysts. The results (Table 1) showed that the vield of the expected product **3a** depended on the nature of the base, temperature, and solvent. The reaction proceeded smoothly to give addition product **3a** in high yield in the presence of DABCO after 1 h. However, when 4-(N,N-dimethylamino)pyridine (DMAP) or Et₃N (10 mol %) was applied, no product was observed after 10 h (Table 1, entries 2 and 3). And when DBU or DABCO was employed as catalyst, product 3a was obtained in 56% or 63% yields, respectively, at room temperature. In further investigation, we attempted to improve the yield by adjusting the temperature of reaction. Interestingly, the yield reached 95% by using 2 mol % DABCO in DMF at -20 °C. Solvent effects were also investigated. The experiment was indicated that compound **3a** could be obtained in 95% yields in DMF, but when THF, toluene, dioxane, and CH₂Cl₂ were employed, the reaction was severely retarded (Table 1, entries 6–10). Meanwhile, when the reaction carried out neat conditions, product 3a was obtained in lower yield (Table 1, entry 11). Thus, an optimized reaction condition was established using DABCO as catalyst and DMF as solvent.

With established catalytic system, we set out to explore the scope of this sequential process. And the results were summarized in Table 2. As shown in Table 2, various cyclic 1,3-dicarbonyl compounds were employed as nucleophiles to give corresponding 2*H*-pyran-2-ones products in good to high yields (Table 2, entries 1–7).





^{*} Corresponding author. Tel./fax: +86 (20) 39352620; e-mail address: hua.cao@ mail.scut.edu.cn (H. Cao).

 Table 1

 Addition reaction of 1a to 2a using various nitrogen-based organocatalysts^a



Catalyst ^b	T (°C)	Solvent	Time (h)	Yield ^c (%)
_	rt	DMF	1	_
DMAP	rt	DMF	10	_
Et ₃ N	rt	DMF	10	_
DBU	rt	DMF	1	56
DABCO	rt	DMF	1	63
DABCO	10	DMF	1	66
DABCO	0	DMF	1	78
DABCO	-20	DMF	1	95
DABCO	-30	DMF	1	94
DABCO	-50	DMF	1	88
DABCO	-20	THF	1	77
DABCO	-20	Toluene	1	69
DABCO	-20	Dioxane	1	84
DABCO	-20	CH_2Cl_2	1	82
DABCO	-20			13
	Catalyst ^b — DMAP Et ₃ N DBU DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO DABCO	Catalyst ^b T (°C) rt DMAP rt Et ₃ N rt DBU rt DABCO rt DABCO 10 DABCO -20 DABCO -30 DABCO -20 DABCO -20	Catalystb $T (^{\circ}C)$ SolventrtDMFDMAPrtDMFEt_3NrtDMFDBUrtDMFDABCO10DMFDABCO0DMFDABCO-20DMFDABCO-30DMFDABCO-20THFDABCO-20THFDABCO-20THFDABCO-20TolueneDABCO-20CH2Cl2DABCO-20CH2Cl2	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

 $^a\,$ Reaction conditions: $1a\,(0.5\,$ mmol), $2a\,(0.6\,$ mmol), $2\,$ mol $\%\,$ catalyst, temperature -50 to rt.

^b DMAP=4-Dimethylaminopyridine, DABCO=1,4-Diazabicyclo [2.2.2] octane, DBU=1,8-Diazabicyclo[5.4.0]undec-7-ene.

^c GC yields.

It was obvious that substituents on the 5- of cyclic 1,3-dicarbonyl compounds had no negative effects on the reaction. When **2a** was replaced by **2b** in this reaction, it was found that a range of substitutions in the cyclic 1,3-dicarbonyl were well tolerated under the optimum conditions (Table 2, entries 8–11). This indicated that **2b** was also suitable for this DABCO-catalyzed reaction. We then extended the scope of nucleophiles to activated methylenes **1h** and **1i**. When the reactions carried out using **2a** or **2b** as substrates, the corresponding products obtained with good yields. However, the reaction was chaos using **2c** as substrate and the desired products **3hc** and **3ic** was obtained in low yield (GC) under the optimum conditions. The crude products were separated by column chromatography, which was a mixture rather than a pure sample. Finally, the molecular structure of representative product **3ba** was determined by X-ray crystallography (Fig. 1).

These promising results encouraged us to extend the scope of the reaction by using other 3-dicarbonyl compounds, such as acetylacetone **1j** and dibenzoylmethane **1k**, in DMF at -20 °C. Interestingly, only the enol form product **3ja** was detected by using **1j** as substrate and the corresponding product of 2*H*-pyran-2-one was not found, while the keto form product **3ka** was only obtained by using **1k** as substrate. This may be explained by the p- π conjugation of benzene and carbonyl within **1k** but **1j** without any (Scheme 1).

On the other hand, 4*H*-pyran is one of the most fundamental classes of five-membered heterocycle, which has directly stimulated more and more interest in both industrial and academic fields over the past decades. Thus, under the conditions depicted in Scheme 2, an efficient DABCO-catalyzed three components reaction was developed to construct 4*H*-pyran derivatives under mild condition¹³ (Scheme 2). The most advantages were short reaction time for only 0.5 h and the high yield.¹⁴

Table 2



4043

Table 2 (continued)

Entry	Activated methylene	Alkynes	Product	Yield ^a (%)
5	Ph le	2a	Jea	89
6	If	2a	3fa	86
7	p-FPh 1g	2a	3ga	78
8	16	^{CO₂Et} ∥ CO₂Et 2b	Eto	80
9	1c	2b	EtO O 3cb	85
10	1d	2b	Eto	81
11	1f	2b	Ею Эfb	88
12	lh	2a	or o	89 ⁹
13	li OEt 1i	2b	EtO O Jib	86 ⁹

Table 2 (continued)



^a Isolated yields.

^b GC yields.



Fig. 1. X-ray crystal structure of compound 3ba.



Scheme 1. The reactions of acetylacetone or dibenzoylmethane with 2a.



Scheme 2. Three component reaction synthesis of 4H-pyran.

On the basis of experimental results, a tentative mechanism for the DABCO promoted Michael type addition at the betaposition was proposed in Scheme $3.^{15}$ Intermediate **A** was initially formed by the reaction between DABCO and **2a**. Then **1a** underwent deprotonation by intermediate **A** to give intermediate **B** and **C**, respectively. The intermediate **B** would attack the betaposition of intermediate **C** to generate intermediate **D**, which subsequently gave the intermediate **E** and regenerated the catalyst. Finally, the product **3aa** was formed by following cyclization of intermediate **E**.



Scheme 3. Possible reaction mechanisms.

3. Conclusions

In conclusion, we have developed a DABCO-catalyzed addition of 1,3-dicarbonyl compounds to alkynes for the formation of C–C bonds. The transformation has provided a facile route for the synthesis of pyran derivatives. This reaction has explored the new possibilities of *N*-catalysts for Michael addition of nucleophiles with alkynoates. Efforts were underway to extend the scope of DABCO in other C–C bond forming transformations and to synthesize interesting heterocylces by this reaction.

4. Experimental

4.1. General

¹H and ¹³C NMR spectra were recorded using a Bruker Avance 400 MHz NMR spectrometer. IR spectra were obtained either as potassium bromide pellets or as liquid films between two potassium bromide pellets with a Bruker Vector 22 spectrometer. Mass spectra were recorded on a Shimadzu GC–MS-QP5050A spectrometer at an ionization voltage of 70 eV equipped with a DB-WAX capillary column (internal diameter: 0.25 mm, length: 30 m). Elemental analyses were performed with a Vario EL elemental analyzer. TLC was performed by using commercially prepared 100–400 mesh silica gel plates (GF254) and visualization was effected at 254 nm.

4.2. General procedure for the synthesis of methyl 2,5-dioxo-5,6,7,8-tetrahydro-2*H*-chromene-4-carboxylate (3aa)

To the mixture of cyclohexane-1,3-dione (**1a** 0.5 mmol) and dimethyl but-2-ynedioate (**2a** 0.6 mmol), was added the solution of DABCO (2 mol %) in DMF (2.0 mL). The reaction mixture was stirred at -20 °C for 1 h. The solvent was removed and the crude product was separated by column chromatography to give a pure sample of **3aa**.

4.2.1. Methyl 2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3aa**). ¹H NMR (400 MHz, CDCl₃) δ 6.19(s, 1H), 3.93(s, 3H), 2.91(t, *J*=6.0 Hz, 2H), 2.58 (t, *J*=6.0 Hz, 2H), 2.15–2.21(m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 192.4, 175.4, 165.9, 158.7, 145.9, 112.4, 112.1, 53.2, 36.5, 28.5, 19.8. MS (EI) *m/z* (%): 222, 194, 163, 138, 93. C₁₁H₁₀O₅: calcd C, 59.46; H, 4.54; found: C, 59.09; H, 4.56.

4.2.2. Methyl 7-methyl-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3ba**). ¹H NMR (400 MHz, CDCl₃) δ 6.18(s, 1H), 3.93(s, 3H), 2.88–2.92 (m, 1H), 2.58–2.67 (m, 2H), 2.39–2.47 (m, 1H), 2.23–2.30 (m, 1H), 1.18 (d, *J*=6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 192.4, 174.8, 165.8, 158.8, 145.79, 112.0, 111.9, 53.2, 44.8, 36.3, 27.8, 20.7; MS (EI) *m/z* (%): 236, 177, 138, 93. C₁₂H₁₂O₅: calcd C, 61.01; H, 5.12; found: C, 61.42; H, 5.10.

4.2.3. Methyl 7,7-dimethyl-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate(**3ca**). ¹H NMR (400 MHz, CDCl₃) δ 6.18(s, 1H), 3.92(s, 3H), 2.76 (s, 2H), 2.44 (s, 2H), 1.16 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 192.4, 174.0, 165.8, 159.0, 145.6, 111.8, 11.39, 53.1, 50.5, 42.0, 32.5, 28.2; MS (EI) *m*/*z* (%): 250, 194, 166, 138, 93; C₁₃H₁₄O₅: calcd C, 62.39; H, 5.64; found: C, 61.86; H, 5.66.

4.2.4. Methyl 7-isopropyl-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3da**). ¹H NMR (400 MHz, CDCl₃) δ 6.16 (s, 1H), 3.92 (s, 3H), 2.84–2.89 (m, 1H), 2.63–2.74 (m, 2H), 2.26–2.34 (m, 1H), 2.03–2.10 (m, 1H), 1.70–1.74 (m, 1H), 1.00 (d, *J*=8.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 192.8, 175.5, 165.8, 158.8, 145.7, 111.9, 111.8, 53.0, 40.6, 38.8, 32.2, 31.6, 19.3, 19.2; MS (EI) *m/z*(%): 264, 205, 194, 166, 138, 93, 69; C₁₄H₁₆O₅: calcd C, 63.63; H, 6.10; found: C, 63.97; H, 6.12.

4.2.5. Methyl 2,5-dioxo-7-phenyl-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate(**3ea**). ¹H NMR (400 MHz) δ 7.36–7.39 (m, 2H), 7.25–7.27 (m, 2H), 6.19 (s, 1H), 3.92 (s, 3H), 3.51–3.57 (m, 1H), 3.08–3.12 (m, 2H), 2.74–2.86 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 191.7, 174.5, 165.7, 158.7, 145.7, 140.8, 129.1, 127.7, 126.5, 112.2, 112.0, 53.2, 43.7, 38.0, 35.9, 14.1. MS (EI) *m/z* (%): 298, 228, 193, 77, 55; C₁₇H₁₄O₅: calcd C, 68.45; H, 4.73; found: C, 68.07; H, 4.75.

4.2.6. Methyl 7-(furan-2-yl)-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3fa**). ¹H NMR (400 MHz, CDCl₃) δ 7.37 (s, 1H), 6.33 (s, 1H), 6.20 (s, 1H), 6.12 (d, *J*=3.0 Hz, 1H), 3.93 (s, 3H), 3.63–3.68 (m, 1H), 3.15–3.20 (m, 2H), 2.82–2.91 (m, 1H), 2.75–2.90 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 190.9, 173.6, 165.7, 158.6, 153.7, 145.6, 142.3, 112.3, 112.1, 110.4, 105.7, 53.2, 40.9, 33.2, 31.6. MS (EI) *m/z* (%): 288, 261, 227, 194, 94, 66; C₁₅H₁₂O₆: C, 62.50; H, 4.20; found: C, 62.11; H, 4.22.

4.2.7. Methyl 7-(4-fluorophenyl)-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3ga**). ¹H NMR (400 MHz, CDCl₃) δ 7.21–7.24 (m, 2H), 7.06–7.10 (m, 2H), 6.23 (s, 1H), 3.95 (s, 3H), 3.51–3.58 (m, 1H), 3.07–3.09 (m, *J*=8.0 Hz, 2H), 2.74–2.88 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 191.3, 174.1, 165.7, 160.9, 158.5, 145.6, 136.4, 128.1, 128.0, 116.2, 116.0, 112.4, 53.2, 43.8, 37.5, 36.1. MS (EI) *m/z* (%): 316, 267, 223, 194, 77. C₁₇H₁₃O₅: calcd C, 64.56; H, 4.14; found: C, 64.09; H, 4.17.

4.2.8. Ethyl 7-methyl-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3bb**). ¹H NMR (400 MHz, CDCl₃) δ 6.17 (s, 1H), 4.38–4.43 (m, 2H), 2.86–2.82 (m, 1H), 2.57–2.67 (m, 2H), 2.30–2.44 (m, 1H), 2.23–2.27 (m, 11.8 Hz, 1H), 1.36 (t, *J*=7.2 Hz, 3H), 1.17 (d, *J*=6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 192.3, 174.7, 165.4, 158.9, 146.1, 112.0, 111.9, 62.6, 44.8, 36.3, 27.8, 20.7, 13.9. MS (EI) *m/z* (%): 250, 221, 177, 93, 45.C₁₃H₁₄O₅: calcd C, 62.39; H, 5.64; found: C, 62.87; H, 5.61.

4.2.9. Ethyl 7,7-dimethyl-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylateethyl (**3cb**). ¹H NMR (400 MHz, CDCl₃) δ 6.18 (s, 1H), 4.40 (q, *J*=7.2 Hz, 2H), 2.75 (s, 2H), 2.45 (s, 2H), 1.37 (t, *J*=7.2 Hz, 3H), 1.16 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 192.3, 173.98, 165.37, 159.17, 146.06, 111.7, 111.4, 62.5, 50.6, 42.1, 32.5, 28.2, 13.9. MS (EI) *m*/*z* (%): 264, 235, 191, 43; C₁₄H₁₆O₅: calcd 63.63; H, 6.10; found: C, 64.01; H, 6.08.

4.2.10. 7-Isopropyl-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3db**). ¹H NMR (400 MHz, CDCl₃) δ 6.17 (s, 1H), 4.40 (q, *J*=7.2 Hz, 2H), 2.83–2.89 (m, 1H), 2.63–2.70 (m, 2H), 2.25–2.29 (m, 1H), 2.07–2.11 (m, 1H), 1.67–1.72 (m, 1H), 1.36 (t, *J*=7.2 Hz, 3H), 0.98 (d, *J*=6.4 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 192.7, 175.3, 165.4, 158.9, 146.1, 112.0, 111.8, 62.6, 40.8, 38.9, 32.3, 31.6, 19.3, 19.3, 13.8. MS (EI) *m/z* (%): 278:C₁₅H₁₈O₅: calcd C, 64.74; H, 6.52; found: C, 65.11; H, 6.50.

4.2.11. Ethyl 7-(furan-2-yl)-2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-4-carboxylate (**3fb**). ¹H NMR (400 MHz, CDCl₃) δ 7.31–7.32 (m, 1H), 6.87 (s, 1H), 6.28–6.30 (m, 1H), 6.08–6.10 (m, 1H), 4.15(d, J=7.2 Hz, 2H), 3.49–3.54 (m, 1H), 2.78–2.84 (m, 2H), 2.65–2.72 (m, 2H), 1.23 (t, J=7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 190.9, 173.3, 166.7, 158.0, 155.5, 141.2, 137.3, 111.7, 110.1, 104.4, 61.0, 44.37, 37.5, 32.0, 13.9. MS (EI) *m/z* (%): 304, 273, 229, 193, 66; C₁₆H₁₄O₆: C, 63.57; H, 4.67; found: C, 63.15; H, 4.70.

4.2.12. Dimethyl 6-methyl-2-oxo-2H-pyran-4,5-dicarboxylate (**3ha**). ¹H NMR (400 MHz, CDCl₃) δ 6.49 (s, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 2.49 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 164.7, 164.6, 159.7, 145.7, 113.7, 109.1, 53.2, 52.7, 19.3. MS (EI) *m*/*z* (%): 221, 195, 125, 93, 43. C₁₀H₁₀O₆: calcd C, 53.10; H, 4.46; found: C, 53.41; H, 4.44.

4.2.13. Diethyl 6-methyl-2-oxo-2H-pyran-4,5-dicarboxylate (**3ib**). ¹H NMR (400 MHz, CDCl₃): δ 6.45 (s, 1H), 4.32 (q, *J*=7.2 Hz, 2H), 2.46 (s, 3H), 4.22 (q, *J*=7.2 Hz, 2H), 1.32 (t, *J*=7.2 Hz, 3H), 1.29 (t, *J*=7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 168.1, 165.1, 164.8, 160.0, 147.4, 113.8, 109.7, 63.0, 62.4, 19.3, 14.1.

4.2.14. Dimethyl 6-methyl-2-oxo-2H-pyran-4,5-dicarboxylate (**3ha**). ¹H NMR (400 MHz, CDCl₃) δ 6.49 (s, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 2.49 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 164.7, 164.6, 159.7, 145.7, 113.7, 109.1, 53.2, 52.7, 19.3. MS (EI) *m*/*z* (%): 221, 195, 125, 93, 43. C₁₀H₁₀O₆: calcd C, 53.10; H, 4.46; found: C, 53.41; H, 4.44.

4.2.15. *Diethyl* 6-*methyl*-2-oxo-2H-*pyran*-4,5-*dicarboxylate* (**3ib**). ¹H NMR (400 MHz, CDCl₃): δ 6.45 (s, 1H), 2.46 (s, 3H), 4.32 (q, *J*=7.2 Hz, 2H), 4.22 (q, *J*=7.2 Hz, 2H), 1.32 (t, *J*=7.2 Hz, 3H), 1.29 (t,

 $J{=}7.2\,$ Hz, 3H); $^{13}{\rm C}$ NMR (100 MHz, CDCl₃): δ 168.1, 165.1, 164.8, 160.0, 147.4, 113.8, 109.7, 63.0, 62.4, 19.3, 14.1.

4.2.16. Dimethyl 2-((*E*)-2-hydroxy-4-oxopent-2-en-3-yl)fumarate (**3***ja*). ¹H NMR (400 MHz, CDCl₃): δ 7.04 (s, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 1.88 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 189.8, 166.6, 164.9, 139.7, 131.9, 106.9, 53.0, 52.1, 23.4.

4.2.17. Dimethyl 2-(1,3-dioxo-1,3-diphenylpropan-2-ylidene)succinate (**3ka**). ¹H NMR (400 MHz, CDCl₃) δ 8.10–8.13(m, 4H), 7.53–7.59(m, 2H), 7.45–7.49 (m, 4H), 3.64 (s, 3H), 3.52 (s, 3H), 3.36 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 192.0, 191.4, 169.6, 165.2, 135.5, 134.9, 134.6, 133.8, 130.6, 129.5, 128.8, 128.7, 128.4, 52.5, 52.2, 34.7.

4.2.18. Dimethyl 2-(tert-butylamino)-5-oxo-5,6,7,8-tetrahydro-4Hchromene-3,4-dicarboxylate (**4aa**). ¹H NMR (400 MHz, CDCl₃): δ 8.60 (s, 1H), 4.35 (s, 1H), 3.55 (s, 3H), 3.50 (s, 3H), 2.19–2.61 (m, 6H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 192.1, 169.9, 165.7, 160.8, 156.1, 109.5, 69.5, 48.7, 48.3, 47.0, 30.56, 26.6, 32.7, 23.1, 16.2.

4.2.19. Dimethyl 2-(tert-butylamino)-7,7-dimethyl-5-oxo-5,6,7,8tetrahydro-4H-chromene-3,4-dicarboxylate (**4ab**). ¹H NMR (400 MHz, CDCl₃) δ: 8.70 (s, 1H), 4.51 (s, 1H), 3.72 (s, 3H), 3.65 (s, 3H), 2.48 (s, 2H), 2.33 (s, 2H), 1.41 (s, 9H), 1.14(s, 3H), 1.13 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): 192.4, 169.9, 166.0, 159.4, 156.5, 108.6, 69.6, 48.9, 46.8, 47.2, 48.5, 37.0, 30.4, 26.8, 28.6, 25.6, 23.37.

Acknowledgements

The work was financially supported by Foundation for Distinguished Young Talentsin Higher Educationof Guangdong, China.

Supplementary data

Supplementary data related to this article can be found online at doi:10.1016/j.tet.2012.03.047.

References and notes

(a) Bartók, M. Chem. Rev. 2010, 110, 1663–1705; (b) McGarrigle, E. M.; Myers, E. L.; Illa, O.; Shaw, M. A.; Riches, S. L.; Aggarwal, V. K. Chem. Rev. 2007, 107, 5841–5883; (c) Moteki, S. A.; Xu, S.; Arimitsu, S.; Maruoka, K. J. Am. Chem. Soc. 2010, 132, 17074–17076; (d) Zheng, Z.; Perkins, B. L.; Ni, B. J. Am. Chem. Soc.

2010, *132*, 50–51; (e) Marcos, V.; Alemn, J.; Ruano, J. L. G.; Marini, F.; Tiecco, M. *Org. Lett.* **2011**, *13*, 3052–3055; (f) Yoshida, A.; Ikeda, M.; Hattori, G.; Miyake, Y.; Nishibayashi, Y. *Org. Lett.* **2011**, *13*, 592–595.

- (a) Zanatta, N.; Barichello, R.; Bonacorso, H. G.; Martins, M. A. P. Synthesis 1999, 5, 765–768; (b) Hirase, K.; Iwahama, T.; Sakaguchi, S.; Ishii, Y. J. Org. Chem. 2002, 67, 970–973; (c) Verhé, R.; De Kimpe, N.; Courtheyn, D.; De Buyck, L.; Schamp, N. Tetrahedron 1982, 38, 3649–3660; (d) Guan, H. P.; Hu, C. M. Synthesis 1996, 1363–1370; (e) Islami, M. R.; Abedini-Torghabeh, J.; Fatemi, S. J.; Hassani, Z.; Amiry, A. Synlett 2004, 1707–1710; (f) Yavari, I.; Souri, S.; Sirouspour, M.; Djahaniani, H.; Nasiri, F. Synthesis 2005, 1761–1764; (g) Skouta, R.; Varma, R. S.; Li, C. J. Green Chem. 2005, 7, 571–575.
 (a) Faltin, C.; Fleming, E. M.; Connon, S. J. J. Org. Chem. 2004, 69, 6496–6499; (b)
- (a) Faltin, C.; Fleming, E. M.; Connon, S. J. J. Org. Chem. **2004**, 69, 6496–6499; (b) Saxena, R.; Patra, A.; Batra, S. Synlett **2003**, 1439–1442; (c) Lee, K. Y.; Kim, J. M.; Kim, J. N. Synlett **2003**, 357–360; (d) Yu, C.; Liu, B.; Hu, L. J. Org. Chem. **2001**, 66, 5413–5418; (e) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Chem. Rev. **2003**, 100, 811–891; (f) Shi, M.; Chen, L. H.; Teng, W. D. Adv. Synth. Catal. **2005**, 347, 1781–1789; (g) Shi, M.; Chen, L. H. Chem. Commun. **2003**, 1310–1311.
- (a) Virieux, D.; Guillouzic, A. F.; Cristau, H. J. Heteroat. Chem. 2007, 18, 312–315;
 (b) Yavari, I.; Hazeri, N.; Maghsoodlou, M. T.; Souri, S. J. Mol. Catal. A: Chem. 2007, 264, 313–317;
 (c) Stewart, I. C.; Bergman, R. G.; Toste, F. D. J. Am. Chem. Soc. 2003, 125, 8696–8697;
 (d) Wang, X.; Li, S.; Jiang, Y. J. Phys. Chem. A. 2005, 109, 10770–10775;
 (e) Liu, H. L.; Jiang, H. F.; Wang, Y. G. Chin. J. Chem. 2007, 25, 1023–1026;
 (f) Gimbert, C.; Lumbierres, M.; Marchi, C.; Moreno-Mañas, M.; Sebastián, R. M.; Vallribera, A. Tetrahedron 2005, 61, 8598–8605.
- 5. Hanédanian, M.; Loreau, O.; Sawicki, M.; Taran, F. Tetrahedron 2005, 61, 2287–2294.
- 6. Liu, H. L.; Jiang, H. F. Tetrahedron 2008, 64, 2120-2125.
- (a) Flematti, G. R.; Ghisalberti, E. L.; Dixon, K. W.; Trengove, R. D. J. Agric. Food Chem. 2009, 57, 9475–9480; (b) D'Annibale, A.; Ciaralli, L.; Bassetti, M.; Pasquini, C. J. Org. Chem. 2007, 72, 6067–6074.
- (a) Chattapadhyay, T. K.; Dureja, P. J. Agric. Food Chem. 2006, 54, 2129–2133; (b) Leutbecher, H.; Williams, L. A. D.; Rosner, H.; Beifuss, U. Bioorg. Med. Chem. Lett. 2007, 17, 978–982; (c) Shen, Q.; Shao, J.; Peng, Q.; Zhang, W.; Ma, L.; Chan, A. S. C.; Gu, L. J. Med. Chem. 2010, 53, 8252–8259.
- 9. (a) Liu, Z.; Meinwald, J. J. Org. Chem. **1996**, 61, 6693–6699; (b) Abe, I.; Takahashi, Y.; Lou, W.; Noguchi, H. Org. Lett. **2003**, 5, 1277–1280.
- (a) Liu, W. B.; Jiang, H. F.; Qiao, C. L. Tetrahedron **2009**, 65, 2110–2115; (b) Liu,
 W. B.; Jiang, H. F.; Zhu, S. F.; Wang, W. Tetrahedron **2009**, 65, 7985–7988; (c) Liu,
 W. B.; Jiang, H. F.; Zhang, M.; Qi, C. R. J. Org. Chem. **2010**, 75, 966–968.
- (a) Cao, H.; Jiang, H. F.; Yuan, G. Q.; Chen, Z. W.; Qi, C. R.; Huang, H. W. Chem. — Eur. J. 2010, 16, 10553–10559; (b) Jiang, H. F.; Yao, W. J.; Cao, H.; Huang, H. W. J. Org. Chem. 2010, 75, 5347–5350; (c) Cao, H.; Jiang, H. F.; Mai, R. H.; Zhu, S. F.; Qi, C. R. Adv. Synth. Catal. 2010, 352, 143–152; (d) Cao, H.; Wang, X. J.; Jiang, H. F.; Zhu, Q. H.; Zhang, M.; Liu, H. Chem.—Eur. J. 2008, 14, 11623–11633; (e) Cao, H.; Jiang, H. F.; Yao, W. J.; Liu, X. H. Org. Lett. 2009, 11, 1931–1933; (f) Cao, H.; Jiang, H. F.; Huang, H. W. Synthesis 2011, 7, 1019–1036; (g) Zhang, M.; Jiang, H. F.; Liu, H. L.; Zhu, Q. H. Org. Lett. 2007, 9, 4111–4113.
- (a) Maeda, S.; Y.Obora; Ishii, Y. *Eur. J. Org. Chem.* **2009**, 4067–4072; (b) Crombie, L.; Eskins, M.; Games, D. E.; Loader, C. *J. Chem. Soc., Perkin Trans.* **1 1979**, 478–482; (c) Baker, S. R.; Begley, M. J.; Crombie, L. *J. Chem. Soc., Perkin Trans.* **1 1981**, 182–189.
- 13. Yavari, I.; Adib, M.; Sayahi, M. H. J. Chem. Soc., Perkin Trans. 1 2002, 2343-2346.
- Maghsoodlou, M. T.; Yavari, I.; Nassiri, F.; Djahaniani, H.; Razmjoo, Z. Monatsh. Chem. 2003, 134, 1585–1591.
- 15. Zhao, W.; Hua, R. Tetrahedron 2007, 63, 11803-11808.